Molnupiravir Does Not Reduce Risk For Hospitalization Or Death In High-Risk Outpatients With COVID-19 Who Receive The Antiviral Within Five Days Of Symptoms, Trial Indicates

MedPage Today (10/11, Hein) reports “molnupiravir failed to reduce the risk for hospitalization or death in high-risk” outpatients with COVID-19 “who took the oral antiviral within 5 days of symptoms, a large open-label multicenter trial found.” In the “m...